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Despite major improvements in imaging, radiation, and surgery, the 
prognosis for patients with Glioblastoma multiforme (GBM) remains clinically 
challenging. New treatment strategies are badly needed to reduce the mortality 
and morbidity associated with this disease. The resistance of these tumors to 
conventional treatments makes GBM patients ideal candidates for molecularly 
targeted therapies and several agents are currently being developed(1). Because 
GBM is genetically heterogeneous, combination therapies or the use of 
multikinase inhibitors are more likely to achieve the greatest therapeutic 
benefit(2,3). However, genes that can be productively targeted for effective 
therapies in patients remain to be identified. The overall objective of this project 
was to better understand the signaling pathways driving cell survival so that new 
targets can be identified in gliomas. These studies will lead to an increased 
understanding of the proteins that are altered in this disease and should provide 
promising opportunities to develop better treatment strategies based on specific 
molecular targets.  
Two parallel pathways, which are both activated in GBM, converge on 
downstream survival signaling cascades. Studies have demonstrated that 
blocking only one pathway often leads to a transient response (e.g., delayed time 
to progression), but tumors eventually progress(4). More effective therapies are 
likely to be those that inhibit more than one target or pathway(5). Targeting anti-
apoptotic Bcl-2 proteins in combination with RAS/MAPK or AKT/mTOR inhibition 
is a rationale approach.  
To determine if inhibiting both the RAS/MAPK and AKT/mTOR pathways 
in combination results in increased apoptosis in glioma cells, I compared the 
level of apoptosis in cells treated with each inhibitor alone and in combination. 
Treatment of glioma cells with a MEK inhibitor in combination with a PI(3)K 
inhibitor has not previously been reported and therefore represents a new 
approach in the field. We already know that just inhibiting RAS/MAPK or 
AKT/mTOR alone results in cell cycle arrest but not death. I tested the effect on 
cell death when combining the inhibitors of both pathways, and saw an increase 
in cell death. I determined the growth inhibitory and apoptotic sensitivity of 
several human glioma cell lines to inhibition of both RAS/MAPK and AKT/mTOR 
pathways. Due to the heterogeneous nature of GBM, I predicted and saw that 
these cell lines display varying levels of sensitivity to MEK/PI(3)K inhibition. 
These differences can then be used in the future to further define the 
mechanism(s) by which the AKT and MAPK pathways mediate survival signaling 
in glioma cells.  
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THE EFFECTS OF HOST PHYSIOLOGICAL CONDITIONS ON THE EXPRESSION OF ICSP IN SHIGELLA FLEXNERI 
 
Shigella flexneri is a gram-negative bacterium capable of causing diarrhea and dysentery known as shigellosis. It is 
estimated there are 167.4 million shigellosis episodes throughout the world each year causing 1.1 million deaths. Shigella 
invades cells in the lower intestine through an induced phagocytosis. Once in the cytoplasm, bacteria move from one cell 
to another using actin-based motility. The Shigella outer membrane protease IcsP regulates actin-based motility and cell-
to-cell spread by cleaving the actin assembly protein IcsA from the bacterial cell surface. We hypothesize that IcsP may 
serve additional functions during infection. By examining which environmental signals trigger icsP expression, we aim to 
identify other regions of the body where IcsP might function. Shigellae are exposed to an array of environmental 
conditions in the body. We examined the presence of bile salts, low pH, and anaerobic conditions in this study. 
Expression of icsP and IcsP levels were assessed in bacteria grown under each of these physiological conditions using β-
galactosidase assays and western blots, respectively. Growth of Shigella strains was reduced in the presence of 
deoxycholate, a common bile salt, as compared to the control. In stationary growth phase, icsP expression increased 
when the bacteria were grown in the presence of bile salts. Growth of Shigella in medium buffered at pH 5.5 was slightly 
elevated (<10% more growth) when compared to bacteria grown in medium at pH 7.4. We also found that anaerobic 
conditions negatively impact the growth of Shigella. Expression of icsP has not yet been measured under this condition.  
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INTRODUCTION
Despite major improvements in imaging, radiation, and surgery, the prognosis for patients with 
Glioblastoma multiforme (GBM) remains clinically challenging. New treatment strategies are badly 
needed to reduce the mortality and morbidity associated with this disease. The resistance of these 
tumors to conventional treatments makes GBM patients ideal candidates for molecularly targeted 
therapies and several agents are currently being developed(1). Because GBM is genetically 
heterogeneous, combination therapies or the use of multikinase inhibitors are more likely to achieve 
the greatest therapeutic benefit(2,3). However, genes that can be productively targeted for effective 
therapies in patients remain to be identified. The overall objective of this project was to better 
understand the signaling pathways driving cell survival so that new targets can be identified in 
gliomas. These studies will lead to an increased understanding of the proteins that are altered in this 
disease and should provide promising opportunities to develop better treatment strategies based on 
specific molecular targets. 
Two parallel pathways, which are both activated in GBM, converge on downstream survival 
signaling cascades. Studies have demonstrated that blocking only one pathway often leads to a 
transient response (e.g., d layed time to progression), but tumors eventually progress(4). More 
effective therapies are likely to be those that inhibit more than one target or pathway(5). Targeting 
anti-apoptotic Bcl-2 proteins in combination with RAS/MAPK or AKT/mTOR inhibition is a rationale 
approach. 
To determine if inhibiting both the RAS/MAPK and AKT/mTOR pathways in combination results 
in increased apoptosis in glioma cells, I compared the level of apoptosis in cells treated with each 
inhibitor alone and in combination. Treatment of glioma cells with a MEK inhibitor in combination with 
a PI(3)K inhibitor has not previously been reported and therefore represents a new approach in the 
field. We already know that just inhibiting RAS/MAPK or AKT/mTOR alone results in cell cycle arrest 
but not death. I tested the effect on cell death when combining the inhibitors of both pathways, and 
saw an increase in cell death. I determined the growth inhibitory and apoptotic sensitivity of several 
human glioma cell lines to inhibition of both RAS/MAPK and AKT/mTOR pathways. Due to the 
heterogeneous nature of GBM, I predicted and saw that these cell lines display varying levels of 
sensitivity to MEK/PI(3)K inhibition. These differences can then be used in the future to further define 
the mechanism(s) by which the AKT and MAPK pathways mediate survival signaling in glioma cells. 
BACKGROUND
Glioma Grade and Pr g osis
Grade 1: Pilocytic astrocytomas, Curable by surgery
Very distinct from the other grades
Grade 2: Survival can be as long as 10-15 ye rs
Grade 3: Anaplastic astrocytomas, 2-3 year survival
Grade 4: Glioblastoma multiforme (GBM)
GBMs make up ~50% of all primary brain tumors
~21,800 new cases per year*
Average survival is ~12 months
~13,070 deaths per year
*CA Cancer J Clin 58:71-96 (2008)
Positron Emission Tomography (PET) Scan of GBM Tumor
METHODS
BEZ235
CI-1040
A high-throughput system (SuperArray CASE ELISA) was used 
to determine the optimal concentrations of inhibitors to decrease 
phosphorylation in the two signaling cascades after a 48 hour 
(BEZ235) and 72 hour (CI-1040) treatment period. 
Western Blots were used to verify the inhibition of phosphorylated 
proteins in the pathway (P-ERK, P-AKT, P-p70s6K, and P-MEK) 
and reprobed for total protein and α-tubulin. Flow cytometry was 
used to determine cell cycle arrest and apoptosis. 
The two inhibitors used were CI-1040 (Pfizer), which is a 2nd 
generation MEK inhibitor, and BEZ235 (Novartis), which is a Class I 
phosphatidylinositol-3-kinase (PI3K) tyrosine kinase inhibitor. 
Inhibitors were used alone and in combination to compare levels 
of phosphorylation and apoptosis in the six human GBM cell lines
SF-268, SF-295, SF-538, SNB19, SNB75, and U251. 
Inhibitors used:
CI-1040 and BEZ 235
CI-1040 BEZ 235
Noncompetitive inhibitor of  MEK1            Class I PI(3)K inhibitor 
RESULTS
Dose curve for BEZ 235- determination of the relative concentration required to 
inhibit phosphorylation of AKT (PI3K pathway). The dose curve shows that 0.1 µM of BEZ235  
inhibits phosphorylation of proteins downstream of PI3K in the AKT/mTOR signaling cascade in most of the cell 
lines. 0.1 µM was chosen over 1 µM because at a certain point, there is a risk of cytotoxicity unrelated to 
apoptosis.   
CONCLUSIONS
FUTURE DIRECTIONS
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Different concentrations of inhibitors can be tested to see if higher concentrations are necessary 
when combined. There are also newer generations of compounds being released that may hit their 
targets more effectively and be more stable in the cell than the ones tested here. 
Other proteins known to be involved in apoptosis will be examined, like the anti-apoptotic Bcl-2 
family members, including Bcl-2 and Bcl-xl. If these can be inhibited, cell death may be achieved 
more fully. 
siRNA will also be performed to completely knock out phosphorylated (activated) proteins. Some 
possibilities to target include all three isoforms of Raf (A,B, and C) and PI(3)K, thus disabling the 
pathways for cell survival. 
Cell line:            SNB-19                          U251                          SF-295                        SF-539                          SNB-75                           SF-268
Sensitivity:
CI-1040 (10 µM)
BEZ235 (0.1 µM) 
- +  - +
- - +  +
- +  - +
- - +  +
- +  - +
- - +   +
- +  - +
- - +   +
- +  - +
- - +   +
- +   - +
- - +  +
p-ERK
ERK
P-p70s6k
p70s6k
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RESULTS (cont)
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Dose curve for CI-1040- determination of the relative concentration required to 
inhibit phosphorylation of ERK (MAPK pathway). The dose curve shows that 10 µM 
appears to be the best concentration of CI-1040 to inhibit phosphorylation of proteins downstream 
of MEK in the RAS/MAPK signaling cascade. 
AKT/mTOR and RAS/MAPK Signaling Cascades Active in GBM
0.7% 3.3% 15.7%13.3%
The PI(3)K/mTOR 
and RAS/MAPK 
pathways are both 
active in GBM and 
engage in “cross-
talk” via positive 
and negative 
regulation that 
makes it very 
difficult to inhibit 
both pathways 
simultaneously. 
For the CASE ELISA, a colorimetric determination system is used to 
determine the relative amount of phosphorylated protein in cells. The lower 
the O.D., the lower the amount of phosphorylated protein, and therefore the 
pathways are less active and the cells are less able to proliferate. 
Western blots were performed on cell lysates from cells treated with the indicated inhibitors for 72 hours, with the BEZ235 being refreshed 
every 24 hours. The results how that the CI-1040 inhibited p-ERK, while the BEZ235 compound inhibited p-p70s6k to varying degrees 
between the cell lines, as predicted (red). Interestingly, an increase in phosphorylated ERK can be seen when treated with the PI(3)K inhibitor 
(green), which corresponds to the negative  regulation that AKT has on B-Raf, a protein upstream of ERK in the signaling cascade. 
SNB19 Control (no treatment) SNB19 Combo (both treatments) SF-295 Control (no treatment) SF-295 Combo (both treatments)
A flow cytometer (Guava) was used to determine cell apoptosis and G1 growth arrest to see if the inhibitors were killing the GBM tumor cells. 
Although there wasn’t a large amount of apoptosis (sub G1= brown), there was a visible increase in cell death and cells present in the G1 phase 
(pink) when comparing the control cells and cells treated with the combination of drugs. The green area represents S phase and the blue peak 
represents G2/M phase in the cell cycle. 
53.8%
53.7%
65.1%56.1%
The main conclusion that can be drawn from these experiments is that the CI-1040 and BEZ235 
compounds do inhibit their respective pathways, but there is something in the cell that is keeping the 
combination of them from inducing complete apoptosis. Different concentrations may need to be used 
in combination than the single agent studies indicated. 
The data obtained also show significant “cross-talk” between the two pathways, which could 
also be affecting the combination’s ability to work as effectively as expected. Specifically, an increase in 
P-ERK can be seen when the PI(3)K is inhibited, which may be enough for the cells to survive. This 
was apparent by both the Western blots and CASE ELISA studies (data not shown). The main objective 
now will be to find ways to stop the feedback between the two pathways so that complete cell death can 
be achieved. 
72 hour treatment in RPMI media
48 hour treatment in RPMI media
Sebolt-Leopold, J. S. & English, J. M. Mechanisms of drug 
inhibition of signalling molecules. Nature 441, 457-62 (2006). 
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